NLRP3 and myocardial infarction: Given the effectiveness of the NLRP3-inflammasome inhibitor tested in vitro and the adequate measured in vivo levels of the compound, we therefore hypothesize that in the current model of MI, NLRP3-inflammasome activation was either not present, or if present was not essential for systemic inflammation and final IS and cardiac function after MI.